JOURNAL ARTICLE

[Oral anticoagulation for atrial fibrillation]

Matthias Antz, Joelle Beauport, Wolfgang Vocke
Herzschrittmachertherapie & Elektrophysiologie 2014, 25 (1): 3-11
24562906
The correct oral anticoagulation for prevention of thromboembolic events in patients with atrial fibrillation and a corresponding risk profile is essential. However, anticoagulation is not carried out according to the guidelines in all patients. The direct oral anticoagulants (DOACs) are a new treatment alternative to vitamin K antagonists. The new guidelines of the European Society of Cardiology (ESC), recent study results and the practice guidelines of the European Heart Rhythm Association (EHRA) can help to use DOACs appropriately, to optimize the prevention of thromboembolic events in patients with atrial fibrillation and to reduce complications.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
24562906
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"